Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports

Antimalarial Drugs Market Size, Share Global Analysis Report, 2022 – 2028

report img

Antimalarial Drugs Market Size, Share, Growth Analysis Report By Drug Class (Quinine, Chloroquine, Proguanil, Mefloquine, Pyrimethamine, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce & Other Distribution Channel), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028

Industry Insights

[227+ Pages Report] According to Facts and Factors, the global antimalarial drugs market size was valued at USD 982.50 million in 2021 and is predicted to increase at a CAGR of 4.2% to USD 1207.51 million by 2028. The study examines the market in terms of revenue in each of the major regions, which are classified into countries. The report analyses the global antimalarial drugs market’s drivers and restraints, as well as the impact they have on demand throughout the projection period. In addition, the report examines global opportunities in the antimalarial drugs market.

Global Antimalarial Drugs Market Size

To know more about this report | Request Free Sample Copy

logoMarket Overview

Malaria is an infectious disease transmitted to humans by a bite from an infected female Anopheles mosquito, which transmits parasites into the body. Antimalarial medicines are those that are used to treat and prevent malarial infections. For the treatment of malarial infection, several medications such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others are available on the market. The rise in malaria prevalence in developing nations is a primary factor driving the expansion of the antimalarial medicines industry.

Furthermore, increased government awareness programs and increased research for new antimalarial medications are some of the reasons driving the market's growth. However, in undeveloped countries, a lack of information about healthcare is a key stumbling block to the market's expansion. During the projection period, however, emerging economies' growth potential is expected to provide profitable opportunities for market expansion.

logo Growth Drivers

One of the factors driving the market's growth is the rising number of cases of traveler's malaria. Every year, thousands of individuals travel to malaria-affected areas around the world, increasing the risk of infection. Travelers are urged by regulatory authorities to bring antimalarial drugs with them in order to avoid the growing patient pool and lower the danger of traveler malaria. Many of the major pharmaceutical companies have partnered with Medicine for Malaria Venture (MMV) to explore innovative pharmacological entities for malaria treatment.

Furthermore, increasing support from regional governments is helping to drive the global anti-malaria medicine industry forward. These funds are expected to allow research institutes like Medicines for Malaria Venture (MMV) to continue their quest for promising malaria-targeting lead candidates. The worldwide anti-malaria pharmaceuticals market is projected to be hampered by the adverse effects and dangers associated with anti-malaria treatments.

logo COVID – 19 Impact

One of the major causes driving the expansion of the antimalarial medicine industry is the exponential increase in COVID-19 cases around the world. As chloroquines can affect the acidity at a cell's surface, they can prevent the virus from infecting people. As a result, it is believed that hydroxychloroquine pills will block the virus that causes COVID-19. The rising number of COVID-19 cases around the world, combined with hydroxychloroquine's promise as a treatment, will drive up demand for antimalarial medications to combat the coronavirus. In the near future, market growth will be aided by the government's increased attention on COVID-19 treatment. COVID-19-affected countries are encouraging the Indian government to enhance hydroxychloroquine exports.

The complete research study looks at both the qualitative and quantitative aspects of the Antimalarial Drugs market. Both the demand and supply sides of the market have been investigated. The demand side study examines market income in various regions before comparing it to all of the major countries. The supply side research examines the industry's top rivals, as well as their regional and global presence and strategies. Each major country in North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America is thoroughly investigated.

logoSegmentation Analysis

The global Antimalarial Drugs market is segregated based on drug class and distribution channel.

Based on the drug class, the market for antimalarial drugs was dominated by the chloroquine segment. Furthermore, the segment is expected to grow at the fastest rate during the forecast period, owing to the fact that malaria parasites have successfully developed resistance to the majority of the drugs currently on the market.

Based on the distribution channel, the hospital pharmacy industry has taken the lead due to the growing number of hospitals around the world. Furthermore, antimalarial pharmaceuticals are prescription-only medications that are typically prescribed by specialist healthcare experts in hospitals, boosting the segment's growth. In contrast, due to the increased use of the internet around the world, the e-commerce segment is predicted to develop at the quickest rate during the forecast period.

logoReport Scope

Report Attribute


Market Size in 2021

USD 982.50 Million

Projected Market Size in 2028

USD 1207.51 Million

CAGR Growth Rate

4.2% CAGR

Base Year


Forecast Years


Key Market Players

Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), Zydus Cadila, and Others

Key Segment

By Drug Class, Distribution Channel, and Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logoRegional Landscape

LAMEA accounted for the majority of antimalarial drug market share in 2021 and is expected to maintain this trend, owing to the region's rapid rise in malaria prevalence. Furthermore, the presence of the malaria vector, Anopheles gambiae, in the region, which is difficult to control, is a major factor contributing to the increase in malaria cases. Furthermore, the majority of malaria infections in this region are caused by Plasmodium falciparum, the most lethal type of malaria parasite. As a result, there is a need for early diagnosis of malarial infection in this region, which drives the market growth. The market's expansion is being driven by the ever-changing life sciences industry.

logoCompetitive Landscape

The report contains qualitative and quantitative research on the global Antimalarial Drugs Market, as well as detailed insights and development strategies employed by the leading competitors. The report also provides an in-depth analysis of the market's main competitors, as well as information on their competitiveness. The research also identifies and analyses important business strategies used by these main market players, such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts. The study examines, among other things, each company's global presence, competitors, service offers, and standards.

List of Key Players in the Global Antimalarial Drugs Market:

  • Alvizia Healthcare Pvt. Ltd.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Ipca Laboratories Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
  • Zydus Cadila

The global antimalarial drugs market is segmented as follows:

logoBy Drug Class

  • Quinine
  • Chloroquine
  • Proguanil
  • Mefloquine
  • Pyrimethamine
  • Others

logoBy Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • E-Commerce & Other Distribution Channel

logoBy Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Industry Major Market Players

  • Alvizia Healthcare Pvt. Ltd. 
  • Bayer AG 
  • F. Hoffmann-La Roche Ltd 
  • GlaxoSmithKline Plc 
  • Ipca Laboratories Ltd. 
  • Merck & Co. Inc 
  • Novartis AG 
  • Pfizer Inc. 
  • Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories) 
  • Zydus Cadila

Frequently Asked Questions

The global antimalarial drugs market is segmented on the basis of drug class, distribution channel and region.
Some of the key factors driving the global antimalarial drugs market growth includes the rising number of cases of traveler's malaria, increased government awareness programs and increased research for new antimalarial medications.
The key growth strategies of antimalarial drugs market players include product portfolio expansion, mergers & acquisitions, agreements, geographical expansion, and collaborations.
Latin America is expected to witness substantial growth for global antimalarial drugs market during forecast period.
Some of the major companies operating in the global antimalarial drugs market are Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), Zydus Cadila and among others.